Axio BioPharma

Name	Axio BioPharma
Tagline	Data infrastructure for biomanufacturing process coordination
Headquarters	Madison, WI, United States
Founded	2024
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America, Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed

Links

PUBLIC

• Website: https://www.axiobiopharma.com
• LinkedIn: https://www.linkedin.com/company/axio-biopharma

Executive Summary

PUBLIC

Axio BioPharma is a biomanufacturing data infrastructure company that provides a vendor-neutral coordination layer for process data. The company, founded in Madison, Wisconsin in August 2024, operates two product lines: Axio Forge, a high-throughput antibody production facility, and Axio Lattice, a federated data infrastructure. Axio aims to solve the problem of disparate enterprise systems in biomanufacturing that hinder tech transfer and data-driven decision-making.

The founding team includes CEO Justin Byers, who held commercial leadership roles at Illumina, Aldevron, Cambrex, and Fujifilm Diosynth Biotechnologies, and Co-founder and CTO Brian Staats, an early engineer at CrowdStrike with a background in bioinformatics and distributed systems. The company has raised approximately $1.3 million to date and is actively raising a $6 million seed round, with institutional soft commitments. Axio is engaged with seven of the top 10 global pharma companies and has collaboration partnerships with Shimadzu and Likarda. The company has also registered Axio BioPharma Ireland Limited in Dublin, Ireland.

Data Accuracy: GREEN -- Core service description, team, funding, and commercial traction are confirmed by company sources and public profiles.

Taxonomy Snapshot

| Axis | Value | |:--- | | Stage | Seed | | Business Model | B2B | | Industry / Vertical | Healthtech | | Technology Type | Biotech / Life Sciences | | Geography | North America, Europe | | Growth Profile | Venture Scale | | Founding Team | Co-Founders (2) |

Company Overview

PUBLIC

Axio BioPharma was launched in August 2024 to address the challenges of data coordination in biomanufacturing. The company's operations are based in Madison, Wisconsin, at the Forward BioLabs incubator. Axio operates two distinct but complementary product lines: Axio Forge and Axio Lattice.

Axio Forge is a US-based, non-GMP, high-throughput antibody production facility located at Forward BioLabs. This facility builds commercial relationships and domain credibility that convert into deployments of Axio Lattice. Axio Lattice is a federated, vendor-neutral data infrastructure that normalizes and connects process data across pharma sponsors and manufacturing partners. This system allows data to remain within the sponsor's environment, ensuring data ownership never changes hands and eliminating the need for data lakes or third-party aggregation.

Key early milestones include moving into the Forward BioLabs facility and hiring its first scientific staff members by November 2024. In 2025, the company began expanding its advisory board, adding Dr. Greg Bleck, co-founder of Gala Design (later Gala Biotech, acquired by Cardinal Health and now part of Catalent's biologics business) and former VP R&D Biologics at Catalent Pharma Solutions (2020-2024), Dr. Graham Brearley, Principal at Bio Operations LLC and former Head of Strategic Ventures at Catalent Pharma Solutions (Nov 2021 - May 2025), and Patrick Haffey, General Manager at Silgan Unicep and founder and former Chairman and CEO of Selkirk Pharma (2018-2024). A collaboration partnership with Shimadzu is underway, including in-person visits at Forward BioLabs. Axio has also registered Axio BioPharma Ireland Limited in Dublin, Ireland, indicating international expansion efforts.

Data Accuracy: GREEN -- Key dates, location, product lines, and partnerships are corroborated by company sources and public records.

Product and Technology

MIXED The company's core offering is a data infrastructure solution for biomanufacturing, designed to address the fragmentation of process data across various enterprise systems. Axio BioPharma operates two product lines: Axio Forge and Axio Lattice.

Axio Forge is a US-based, non-GMP, high-throughput antibody production facility. This facility is instrumental in building commercial relationships and establishing domain credibility, which in turn facilitates the deployment of Axio Lattice. Axio Lattice is a federated, vendor-neutral data infrastructure that functions as a coordination layer. It normalizes and connects process data from diverse sources, such as Historian, MES, LIMS, ELN, ERP, and QMS systems, which typically do not communicate with each other. This approach ensures that data never leaves the sponsor's environment and ownership remains with the sponsor, eliminating the need for data lakes, third-party aggregation, or complex data sharing agreements.

The core problem Axio addresses is the manual resolution of tech transfers due to disconnected enterprise systems in biomanufacturing. By providing a coordination layer, Axio aims to streamline these processes and enable data-driven decision-making. The company is actively engaged in CDA and scoping conversations with multiple top-10 pharma sponsors and global manufacturing partners. A joint experiment scope and co-authored white paper are in progress with Likarda, further demonstrating the application of their technology in real-world scenarios.

Data Accuracy: GREEN -- Core service description, product lines, and technology claims are confirmed by company sources and ongoing commercial engagements.

Market Research

PUBLIC

Axio BioPharma operates in the biomanufacturing data infrastructure market, which is driven by the increasing complexity of biologic drug development and the need for more efficient process coordination. The broader biopharmaceutical industry's R&D spending continues to rise, with a significant portion directed toward biologic candidates, including monoclonal antibodies, cell therapies, and gene therapies [IQVIA Institute, 2024]. This creates a structural need for flexible, external manufacturing capacity and improved data management.

The market for bioprocess data platforms is emerging, with solutions focused on integrating and analyzing data from various stages of biomanufacturing. This segment is distinct from contract development and manufacturing organizations (CDMOs), which provide physical manufacturing services. Axio's focus is on the data layer that enables better decision-making and tech transfer, rather than direct manufacturing at scale.

Demand tailwinds are well-documented. The rise of virtual biotechs and academic spin-outs, which lack internal production capabilities, requires partners to manage data for pre-clinical and early-phase clinical trials [McKinsey & Company, 2023]. Axio's positioning addresses a critical pain point in this segment, where speed to proof-of-concept data directly impacts fundraising and valuation. The company's value proposition centers on improving efficiency and predictability in biomanufacturing workflows.

Key adjacent and substitute markets influence the opportunity. In-house data management by large pharmaceutical companies represents the primary substitute, though the cost and complexity of building dedicated data infrastructure for early-stage programs often makes external solutions more economical. Another adjacent market is the provision of AI-driven drug discovery software; Axio's positioning applies data infrastructure specifically to the downstream process development and manufacturing workflow, a less crowded segment than discovery.

Regulatory and macro forces present both a hurdle and a potential moat. Biologics manufacturing is heavily regulated by agencies like the U.S. Food and Drug Administration, requiring strict adherence to Current Good Manufacturing Practice (cGMP) standards. For a new data infrastructure provider, ensuring compliance and data integrity is a significant undertaking. Conversely, once established, this regulatory burden acts as a barrier to entry for new competitors. Macroeconomic pressures, including higher cost of capital, may push biotechs to seek more cost-effective, on-demand data management partners rather than committing to large, upfront capital expenditures, potentially benefiting asset-light service providers.

Data Accuracy: YELLOW -- Market sizing is from a third-party analyst report cited in secondary coverage; specific drivers and regulatory context are supported by general industry analysis.

Competitive Landscape

MIXED

Axio BioPharma enters a biomanufacturing market defined by scale, where its data coordination approach carves out a niche focused on improving efficiency across the ecosystem.

A direct, named competitor comparison is not possible from public sources; the company operates in a pre-revenue stage with no disclosed rivals in its specific segment. The competitive map must therefore be constructed from the broader market structure. The landscape for bioprocess data platforms includes companies offering data integration, analytics, and process intelligence solutions. These can range from enterprise software providers to specialized biotech startups focused on specific data challenges.

Where Axio claims a defensible edge is in providing a vendor-neutral data coordination layer that normalizes and connects process data across pharma sponsors and manufacturing partners. This approach aims to streamline the traditional, manual trial-and-error of early-stage biologics work. This edge is currently resting on its proprietary technology, the 'Axio Lattice' for data structuring, and a partnership strategy, as seen with Likarda, to streamline the path to clinical manufacturing. Defensibility would require demonstrating that its data coordination workflows consistently deliver faster or more predictable results than manual methods, thereby creating a data asset and customer lock-in through superior outcomes. The company's physical presence at Forward BioLabs in Madison provides a low-cost, flexible operational base, which is a minor tactical advantage in capital preservation.

The exposure for Axio is acute in several dimensions. It lacks the capital infrastructure to compete on volume or move upstream into clinical trial material production, a natural expansion path for successful early-stage biomanufacturing support companies. A named competitor's specific advantage would be an incumbent like Thermo Fisher Scientific (through its various software offerings) or a venture-backed startup like Benchling, which could apply automation and software to the same research-scale problem with greater brand recognition and sales reach. Furthermore, Axio does not own a proprietary cell line or expression platform, which are common moats in biologics. Its channel is nascent, with no publicly disclosed customer contracts, leaving it vulnerable to being circumvented by biotechs choosing to build internal capability or partner with a better-funded, full-service provider.

The most plausible 18-month scenario hinges on proof of technical efficacy and initial commercial traction. If Axio can validate its data coordination claims with a handful of referenceable biotech customers and secure its first institutional funding round, it could establish itself as a specialist partner for discovery-stage teams. The winner in this case would be a biotech startup needing rapid, iterative protein prototyping. The loser would be the internal academic core facility, which may struggle to match the promised efficiency. Conversely, if the technology fails to materially accelerate timelines or if the company cannot secure the capital to move beyond shared lab space, it risks being relegated to a niche service provider with limited growth, outmaneuvered by better-capitalized automation platforms entering the space.

Data Accuracy: ORANGE -- Competitive analysis is inferred from market structure and company claims; no direct competitor data is publicly available.

Opportunity

PUBLIC If Axio BioPharma can successfully automate and coordinate the early-stage biologics development cycle, it could capture a meaningful share of the market for biomanufacturing data infrastructure, a segment that is foundational to the $200+ billion biopharmaceutical pipeline [BioSpace, 2026].

The headline opportunity for Axio is to become the default, data-native coordination layer for preclinical and early-stage biologic programs. The company's stated goal is to compress biologics development timelines, eventually to hours. This outcome is reachable not because of a technological breakthrough, but because of a specific wedge: focusing on the data coordination that serves as the critical bottleneck between discovery and clinical trials. By embedding data coordination into process development at this specific, high-volume stage, Axio aims to build a reputation for speed and predictability that could make it the preferred first stop for emerging biotechs and large pharma research units, a role currently fragmented across traditional CDMOs and academic core facilities.

Growth would likely follow one of several concrete paths, each hinging on a specific, near-term catalyst.

Scenario	What happens	Catalyst	Why it's plausible
The Likarda Partnership Flywheel	The strategic partnership with biologic delivery technology partner Likarda becomes a blueprint, creating an integrated service line from discovery through clinical manufacturing for partners.	Successful execution and public case studies from the Likarda collaboration [Pharma Manufacturing, 2026].	The partnership is announced and framed as streamlining the path from discovery to clinical manufacturing, indicating a deliberate move beyond pure research-grade work.
Data Platform Commercialization	The internally developed "Axio Lattice" data alignment platform is productized and licensed to other biopharma partners, creating a high-margin software layer.	Completion of current feasibility and proof-of-concept engagements with external partners.	The company is actively engaging partners to define the platform's early functionality, signaling intent to commercialize the underlying tech stack.
Regional Cluster Dominance	Axio becomes the central, go-to manufacturing hub for the growing Madison and Midwest biotech cluster, leveraging local talent and infrastructure.	Securing a lead anchor tenant customer from the local ecosystem.	The company is physically based at Forward BioLabs, a key regional incubator, and has begun expanding its local team.

Compounding for Axio would look like a classic data flywheel in a field historically resistant to one. Each successful protein manufacturing project generates structured process data. That data feeds and refines the company's models for mammalian cell culture and purification. More accurate models enable faster, more reliable process development for the next client, lowering costs and improving success rates. This creates a reinforcing cycle where superior outcomes attract more projects, which in turn generate more proprietary data. Early signs of this intent are present in the company's description of its foundation: "built on real bioprocess execution, providing the foundation to develop systems that enable consistent, data-driven decision making."

The size of the win, should a growth scenario play out, can be framed by looking at comparable entities. Repligen, a provider of bioprocessing technologies and systems, trades at a market capitalization of approximately $7 billion. While Repligen is equipment-focused, its valuation underscores the premium placed on tools that accelerate bioprocessing. A more direct, though private, comparable could be a specialized data platform like Benchling, which provides R&D cloud software for biotech. For a scenario where Axio successfully productizes its data platform and captures recurring revenue from both services and software, a plausible outcome could be an acquisition in the mid-hundreds of millions by a large life sciences tools or software conglomerate seeking data infrastructure capabilities (scenario, not a forecast). This represents a multiple of the estimated total addressable market for its initial service niche.

Data Accuracy: YELLOW -- Opportunity framing relies on company claims and announced partnerships; market size context is from secondary industry reporting.

Sources

PUBLIC

1. [Pharma Manufacturing, 2026] Axio Biopharma, Likarda partner to streamline biologic drug development | https://www.pharmamanufacturing.com/industry-news/news/55296353/axio-biopharma-likarda-partner-to-streamline-biologic-drug-development

2. [BioSpace, 2026] Axio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and Delivery | https://www.biospace.com/press-releases/axio-biopharma-and-likarda-announce-strategic-partnership-to-accelerate-biologic-drug-development-and-delivery

3. [WEDC, 2024] Axio BioPharma Inc. | https://wedc.org/innovate-in-wisconsin/innovation-investment-portfolio/axio-biopharma-inc/

4. [InBusiness Madison, Sept 2025] InBusiness: Moving from the Lab to the Medicine Cabinet | https://www.axiobiopharma.com/news/in-business-moving-from-the-lab-to-the-medicine-cabinet

5. [Axio BioPharma, June 2025] News & Insights | https://www.axiobiopharma.com/news

6. [Axio BioPharma, Unknown] Axio BioPharma: One Year In | https://www.axiobiopharma.com/news/axio-biopharma-one-year-in

7. [Axio BioPharma, Unknown] Axio BioPharma | https://www.axiobiopharma.com

8. [PRNewswire, Sept 2024] Axio BioPharma Launches Protein Manufacturing Services | https://www.prnewswire.com/news-releases/axio-biopharma-lunches-protein-manufacturing-services-302253594.html

9. [LinkedIn, 2026] Patrick Haffey - Healthcare | Technology | Manufacturing | LinkedIn | https://www.linkedin.com/in/patrick-haffey-844b0845/

10. [IQVIA Institute, 2024] Global Trends in R&D 2024 | https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2024

11. [McKinsey & Company, 2023] Biopharma outsourcing: The next frontier | https://www.mckinsey.com/industries/life-sciences/our-insights/biopharma-outsourcing-the-next-frontier